246 related articles for article (PubMed ID: 30442825)
41. Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Desideri G; Rajzer M; Gerritsen M; Nurmohamed MT; Giannattasio C; Tausche AK; Borghi C
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):236-242. PubMed ID: 33410912
[TBL] [Abstract][Full Text] [Related]
42. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.
Rey A; Batteux B; Laville SM; Marienne J; Masmoudi K; Gras-Champel V; Liabeuf S
Arthritis Res Ther; 2019 Nov; 21(1):229. PubMed ID: 31703711
[TBL] [Abstract][Full Text] [Related]
43. Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis.
Bellos I; Kontzoglou K; Psyrri A; Pergialiotis V
J Clin Pharm Ther; 2019 Aug; 44(4):525-533. PubMed ID: 30972811
[TBL] [Abstract][Full Text] [Related]
44. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.
Lin CW; Huang WI; Chao PH; Chen WW; Hsiao FY
Int J Clin Pract; 2019 May; 73(5):e13316. PubMed ID: 30681751
[TBL] [Abstract][Full Text] [Related]
45. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
46. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
47. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Choi H; Neogi T; Stamp L; Dalbeth N; Terkeltaub R
Arthritis Rheumatol; 2018 Nov; 70(11):1702-1709. PubMed ID: 29869840
[TBL] [Abstract][Full Text] [Related]
48. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
[TBL] [Abstract][Full Text] [Related]
49. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
[TBL] [Abstract][Full Text] [Related]
51. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
Shin A; Choi SR; Han M; Ha YJ; Lee YJ; Lee EB; Kang EH
Semin Arthritis Rheum; 2022 Oct; 56():152080. PubMed ID: 35973263
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of Febuxostat Versus Allopurinol in Hyperuricemic patients with or without Gout: A meta-analysis.
Fan B; Zhang P; Li X
Neuro Endocrinol Lett; 2020 Oct; 41(4):195-204. PubMed ID: 33307654
[TBL] [Abstract][Full Text] [Related]
53. A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
Lee J; Kim J; Ghang B; Jeong W
Korean J Intern Med; 2023 May; 38(3):427-433. PubMed ID: 36325753
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
White WB; Chohan S; Dabholkar A; Hunt B; Jackson R
Am Heart J; 2012 Jul; 164(1):14-20. PubMed ID: 22795277
[TBL] [Abstract][Full Text] [Related]
55. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
56. Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
Singh JA; Cleveland JD
Eur Heart J; 2019 Sep; 40(36):3046-3054. PubMed ID: 30919894
[TBL] [Abstract][Full Text] [Related]
57. Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.
Ghang BZ; Lee JS; Choi J; Kim J; Yoo B
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35732345
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Ye P; Yang S; Zhang W; Lv Q; Cheng Q; Mei M; Luo T; Liu L; Chen S; Li Q
Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451
[TBL] [Abstract][Full Text] [Related]
59. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
60. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
